<a href="https://www.fiercebiotech.com/biotech/legend-scientific-founder-returns-asco-new-ambition-high-yield-non-gene-edited-car-t" hreflang="en">Legend scientific founder returns to ASCO with new ambition for high-yield, non-gene-editing CAR-T platform</a>
Frank Fan, founder of Legend Biotech, is presenting his new venture, Wondercel Therapeutics, at ASCO 2026, focusing on a high-yield, non-gene-editing CAR-T platform called Revo-U that aims to enhance production scalability and safety in cell therapies. This approach seeks to produce up to 3,000 patient doses from a single donor while avoiding complications related to gene editing, although initial clinical data indicate the platform still requires refinement for optimal efficacy and safety.
The most valuable insight for a professional in healthtech and biotech is that Wondercel Therapeutics' Revo-U platform offers a promising non-gene-editing CAR-T solution with the potential for large-scale production, addressing major industry bottlenecks. This approach could significantly reduce costs and safety concerns associated with gene editing. Monitoring Wondercel's future clinical trials and partnership opportunities could provide strategic insights into scalability and commercial viability in the CAR-T space.